Zheng-Ming Ding

Astrocytes are the most abundant glial cells in the brain and an integrative component of the neural network. Studies have shown that ethanol altered expression of an astrocyte marker, i.e., glial fibrillary acidic protein (GFAP), in two key corticolimbic regions, the medial prefrontal cortex (mPFC) and nucleus accumbens (NAc). These regions comprise anatomically and functionally different subregions, i.e., the prelimbic (PL) and infralimbic (IL) cortex of the mPFC, the shell and core subregions of the NAc. However, ethanol effects on GFAP expression within these subregions remain largely unknown. In addition, effects of pharmacological manipulation of astrocytes on alcohol drinking have been understudied. Western blot was conducted to determine GFAP expression in subregions of the mPFC and NAc after chronic ethanol drinking. Fluorocitrate, an astrocyte-specific metabolic inhibitor, was administered to inhibit astrocytes and was tested on ethanol drinking. Ethanol drinking enhanced GFAP protein expression in the PL cortex and NAc core, but not in the IL cortex or NAc shell. Intra-ventricular administration of fluorocitrate reduced ethanol intake and preference, but increased water consumption during choice ethanol drinking. In addition, fluorocitrate did not affect total fluid consumption or basal locomotor activity. These results indicate that chronic ethanol drinking induced GFAP elevation in a subregion-specific manner within the mPFC and NAc, and that metabolic inhibition of astrocytes selectively attenuated ethanol drinking without non-specific effects on water drinking or general activity. Together, these results suggest that astrocytes may play an important role in ethanol drinking. Highlights: Ethanol drinking enhanced GFAP levels in the PL cortex and NAc core. Fluorocitrate inhibition of astrocytes reduced intermittent ethanol drinking. Fluorocitrate did not alter total fluid consumption or basal locomotor activity.

Introduction: Research has implicated mesocorticolimbic glutamate transmission in alcohol use. The current study focused on glutamate transmission within two key sub-regions, i.e., prelimbic (PL) cortex and nucleus accumbens (NAc) shell, in mediating ethanol reinforcement and drinking in rats. Methods: Intracranial self-administration (ICSA) was conducted to examine effects of inhibition of local glutamate transmission on ethanol ICSA into these sub-regions. Protein levels were determined with Western blot in both sub-regions of alcohol-preferring P and Wistar rats on key glutamate-related proteins that can regulate extracellular glutamate levels. Quantitative microdialysis was performed to measure basal extracellular glutamate concentrations and clearance in the PL cortex following chronic ethanol drinking. An additional study tested effects of centrally administered LDN-212320, a glutamate transporter 1 (GLT-1) activator, on ethanol drinking. Results: Co-infusion of the metabotropic glutamate receptor 2/3 (mGluR2/3) agonist LY379268 with ethanol inhibited ethanol ICSA into these sub-regions. Expression of mGluR3, but not GLT-1, was lower in P than Wistar rats in both sub-regions. Ethanol drinking enhanced basal extracellular glutamate concentrations and reduced glutamate clearance. Intra-ventricular microinjection of LDN-212320 decreased ethanol drinking. Discussion: These results suggest that (a) activation of local glutamate transmission is critical to ethanol reinforcement within the PL cortex and NAc shell, (b) strain difference exists in mGluR3 protein expression between P and Wistar rats, (c) chronic ethanol induces neuro-adaptations characterized by enhanced basal extracellular glutamate transmission, and (d) up-regulation of GLT-1 attenuates ethanol drinking. Taken together, these results further support the importance of glutamate transmission within the PL cortex and NAc shell in mediating ethanol effects.

Background: Our recent studies indicate that astrocytes in a key mesocorticolimbic region play an important role in nicotine reinforcement. Nicotine self-administration elevated the astrocyte marker glial fibrillary acidic protein (GFAP) in the nucleus accumbens (NAc) core. Metabolic inhibition of astrocytes in the NAc core with fluorocitrate attenuated nicotine self-administration and disrupted local extracellular glutamate and dopamine transmission. Cotinine is the major neuroactive metabolite of nicotine, demonstrating its own reinforcing effects and contributing to the development of nicotine reinforcement. Mechanisms underlying cotinine reinforcement remain underexplored. The objective of this study was to investigate the potential involvement of astrocytes in cotinine reinforcement. Methods: GFAP protein expression was measured in key mesocorticolimbic regions with a Western blot following chronic cotinine self-administration. The effects of fluorocitrate on cotinine self-administration and extracellular glutamate and dopamine levels were determined. Results: GFAP protein levels were higher in rats undergoing chronic cotinine self-administration than in those with saline self-administration within the ventral tegmental area (VTA) but not the nucleus accumbens or the medial prefrontal cortex. Intra-VTA microinjection of fluorocitrate inhibited the maintenance of cotinine self-administration. Perfusion of fluorocitrate in the VTA reduced local extracellular levels of glutamate and dopamine. Conclusions: These results indicate that cotinine self-administration augmented GFAP expression in the VTA and that metabolic inhibition of VTA astrocytes attenuated cotinine self-administration and impaired extracellular dopamine and glutamate transmission. Overall, these findings suggest that astrocytes in the VTA may play an important role in cotinine reinforcement, potentially through regulation of local extracellular glutamate and dopamine transmission.

Introduction: Cigarette smoking remains the leading preventable cause of disease and death. Nicotine is the primary reinforcing ingredient in cigarettes sustaining addiction. Cotinine is the major metabolite of nicotine that produces a myriad of neurobehavioral effects. Previous studies showed that cotinine-supported self-administration in rats and rats with a history of cotinine self-administration exhibited relapse-like drug-seeking behavior, suggesting that cotinine may also be reinforcing. To date, whether cotinine may contribute to nicotine reinforcement remains unknown. Nicotine metabolism is mainly catalyzed by hepatic CYP2B1/2 enzymes in rats and methoxsalen is a potent CYP2B1/2 inhibitor. Aims and Methods: The study examined nicotine metabolism, self-administration, and locomotor activity. The hypothesis is that methoxsalen inhibits nicotine self-administration and cotinine replacement attenuates the inhibitory effects of methoxsalen in male rats. Results: Methoxsalen decreased plasma cotinine levels following a subcutaneous nicotine injection. Repeated daily methoxsalen treatments reduced the acquisition of nicotine self-administration, leading to fewer nicotine infusions, lower nicotine intake, and lower plasma cotinine levels. However, methoxsalen did not alter the maintenance of nicotine self-administration despite a significant reduction of plasma cotinine levels. Cotinine replacement by mixing cotinine with nicotine for self-administration dose-dependently increased plasma cotinine levels and enhanced the acquisition of self-administration. Neither basal nor nicotine-induced locomotor activity was altered by methoxsalen. Conclusions: These results indicate that methoxsalen inhibition of cotinine formation impaired the acquisition of nicotine self-administration, and cotinine replacement attenuated the inhibitory effects of methoxsalen on the acquisition of self-administration, suggesting that cotinine may contribute to the initial development of nicotine reinforcement. Implications: Smoking cessation medications targeting nicotine’s effects are only moderately effective, making it imperative to better understand the mechanisms of nicotine misuse. Methoxsalen inhibited nicotine metabolism to cotinine and impaired the acquisition of nicotine self-administration. Cotinine replacement restored plasma cotinine and attenuated the methoxsalen inhibition of nicotine self-administration in rats. These results suggest that (1) the inhibition of nicotine metabolism may be a viable strategy in reducing the development of nicotine reinforcement, (2) methoxsalen may be translationally valuable, and (3) cotinine may be a potential pharmacological target for therapeutic development given its important role in the initial development of nicotine reinforcement.

Cigarette smoking remains the leading preventable cause of disease and death. Nicotine is the primary reinforcing ingredient in cigarettes sustaining addiction. Cotinine is the major metabolite of nicotine that produces a myriad of neurobehavioral effects. Cotinine supported self-administration and rats with a history of intravenous self-administration of cotinine exhibited relapse-like drug-seeking behavior, suggesting cotinine may also be reinforcing. To date, a potential contribution of cotinine to nicotine reinforcement remains unknown. Nicotine metabolism is mainly catalyzed by hepatic CYP2B1 enzyme in the rat and methoxsalen is a potent CYP2B1 inhibitor. The study tested the hypothesis that methoxsalen inbibits nicotine metabolism and self-administration, and that cotinine replacement attenuates the inhibitory effects of methoxsalen. Acute methoxsalen decreased plasma cotinine levels and increased nicotine levels following subcutaneous nicotine injection. Repeated methoxsalen reduced the acquisition of nicotine self-administration, leading to fewer nicotine infusions, disruption of lever differentiation, smaller total nicotine intake, and lower plasma cotinine levels. On the other hand, methoxsalen did not alter nicotine self-administration during the maintenance phase despite great reduction of plasma cotinine levels. Cotinine replacement by mixing cotinine with nicotine for self-administration dose-dependently increased plasma cotinine levels, counteracted effects of methoxsalen, and enhanced the acquisition of self-administration. Neither basal nor nicotine-induced locomotor activity was altered by methoxsalen. These results indicate that methoxsalen depressed cotinine formation from nicotine and the acquisition of nicotine self-administration, and that replacement of plasma cotinine attenuated the inhibitory effects of methoxsalen, suggesting that cotinine may contribute to the development of nicotine reinforcement.

Relapse is a defining feature of smoking and a significant challenge in cessation management. Elucidation of novel factors underlying relapse may inform future treatments. Cotinine, the major metabolite of nicotine, has been shown to support intravenous self-administration in rats, implicating it as one potential factor contributing to nicotine reinforcement. However, it remains unknown whether cotinine would induce relapse-like behaviors. The current study investigated relapse to cotinine seeking in two relapse models, the reinstatement of drug seeking and incubation of drug craving models. In the reinstatement model, rats were trained to self-administer cotinine, underwent extinction of cotinine-associated responses, and were tested for cue-, drug-, or stress-induced reinstatement. Conditioned cues associated with cotinine self-administration, cotinine (1–2 mg/kg), or the pharmacological stressor yohimbine (1.25–2.5 mg/kg) induced reinstatement of cotinine seeking. Female rats displayed more pronounced cue-induced, but not drug- or stress-induced reinstatement than male rats. In the incubation of the craving model, rats were trained to self-administer cotinine and underwent forced withdrawal in home cages. Rats were tested for cue-induced cotinine-seeking on both withdrawal day 1 and withdrawal day 18. Rats exhibited greater cue-induced cotinine-seeking on withdrawal day 18 compared to withdrawal day 1, with no difference between male and female rats. These findings indicate that cotinine induces sex-specific relapse to drug seeking in rats, suggesting that cotinine may contribute to relapse.

With the substantial social and medical burden of addiction, there is considerable interest in understanding risk factors that increase the development of addiction. A key feature of alcohol use disorder (AUD) is compulsive alcohol (EtOH) drinking, where EtOH drinking becomes “inflexible” after chronic intake, and animals, such as humans with AUD, continue drinking despite aversive consequences. Further, since there is a heritable component to AUD risk, some work has focused on genetically-selected, EtOH-preferring rodents, which could help uncover critical mechanisms driving pathological intake. In this regard, aversion-resistant drinking (ARD) takes >1 month to develop in outbred Wistar rats (and perhaps Sardinian-P EtOH-preferring rats). However, ARD has received limited study in Indiana P-rats, which were selected for high EtOH preference and exhibit factors that could parallel human AUD (including front-loading and impulsivity). Here, we show that P-rats rapidly developed compulsion-like responses for EtOH; 0.4 g/L quinine in EtOH significantly reduced female and male intake on the first day of exposure but had no effect after one week of EtOH drinking (15% EtOH, 24 h free-choice paradigm). Further, after 4–5 weeks of EtOH drinking, males but not females showed resistance to even higher quinine (0.5 g/L). Thus, P-rats rapidly developed ARD for EtOH, but only males developed even stronger ARD with further intake. Finally, rats strongly reduced intake of quinine-adulterated water after 1 or 5 weeks of EtOH drinking, suggesting no changes in basic quinine sensitivity. Thus, modeling ARD in P-rats may provide insight into mechanisms underlying genetic predispositions for compulsive drinking and lead to new treatments for AUDs.